ES2233101T3 - Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion. - Google Patents

Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.

Info

Publication number
ES2233101T3
ES2233101T3 ES99968630T ES99968630T ES2233101T3 ES 2233101 T3 ES2233101 T3 ES 2233101T3 ES 99968630 T ES99968630 T ES 99968630T ES 99968630 T ES99968630 T ES 99968630T ES 2233101 T3 ES2233101 T3 ES 2233101T3
Authority
ES
Spain
Prior art keywords
present
directed
fgf
unit dose
another aspect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99968630T
Other languages
English (en)
Inventor
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2233101T3 publication Critical patent/ES2233101T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Composición de dosis unitaria para inducir la angiogénesis en el hombre, que comprende un agente que es FGF- 2 o un fragmento o muteína del mismo angiogénicamente activos, en una cantidad de alrededor de 0, 3 mg a 7, 2 mg aproximadamente, en un vehículo farmacéuticamente activo.
ES99968630T 1998-09-03 1999-08-27 Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion. Expired - Lifetime ES2233101T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14574398P 1998-09-03 1998-09-03
US10410298P 1998-10-13 1998-10-13
US10410398P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
ES2233101T3 true ES2233101T3 (es) 2005-06-01

Family

ID=27379656

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04018831T Expired - Lifetime ES2327839T3 (es) 1998-09-03 1999-08-27 Monodosis de fgf-2 eficaz angiogenicamente y metodo de uso.
ES99968630T Expired - Lifetime ES2233101T3 (es) 1998-09-03 1999-08-27 Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES04018831T Expired - Lifetime ES2327839T3 (es) 1998-09-03 1999-08-27 Monodosis de fgf-2 eficaz angiogenicamente y metodo de uso.

Country Status (8)

Country Link
EP (2) EP2123292B1 (es)
JP (2) JP5329729B2 (es)
AT (2) ATE434440T1 (es)
AU (1) AU6022399A (es)
DE (2) DE69941034D1 (es)
ES (2) ES2327839T3 (es)
HK (1) HK1075409A1 (es)
WO (1) WO2000013701A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
EP1121141A2 (en) 1998-10-13 2001-08-08 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
CA2381780C (en) 1999-08-13 2015-03-10 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
AU2001250821A1 (en) * 2000-03-10 2001-09-24 Chiron Corporation Methods and compositions for the treatment and prevention of erectile dysfunction
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
EP1894570A3 (en) * 2000-06-22 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Methods and compositions for the treatment of peripheral artery disease
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
US20200384079A1 (en) * 2017-04-26 2020-12-10 University Of Cincinnati Compositions of Fibroblast Growth Factor LIgands and Methods of Treating Patients Undergoing Ischemia-Reperfusion Therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4956455A (en) 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
DE3689845T3 (de) * 1985-09-12 2001-11-15 Scios Inc Rekombinanter fibroblast-wachstumsfaktor.
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins

Also Published As

Publication number Publication date
ATE279937T1 (de) 2004-11-15
JP5329729B2 (ja) 2013-10-30
DE69921348T2 (de) 2006-02-09
JP2002524420A (ja) 2002-08-06
WO2000013701A3 (en) 2000-08-03
WO2000013701A9 (en) 2000-10-05
HK1075409A1 (en) 2005-12-16
ATE434440T1 (de) 2009-07-15
ES2327839T3 (es) 2009-11-04
DE69941034D1 (de) 2009-08-06
JP2010163457A (ja) 2010-07-29
EP2123292A1 (en) 2009-11-25
EP1121142B1 (en) 2004-10-20
AU6022399A (en) 2000-03-27
WO2000013701A2 (en) 2000-03-16
DE69921348D1 (de) 2004-11-25
EP1121142A2 (en) 2001-08-08
EP2123292B1 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
PT710114E (pt) Formulacao do factor viii de coagulacao
WO2001098346A3 (en) Methods and compositions for the treatment of peripheral artery disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
NZ283499A (en) Haemophilia medicament; comprises coagulation factor viii or factor ix
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
GB9023701D0 (en) Medical treatment
JP2002524420A5 (es)
WO2000043014A3 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
EP1894570A3 (en) Methods and compositions for the treatment of peripheral artery disease
BR9810095A (pt) Dispositivos para distribuição de droga e métodospara tratamento de infecções virais e microbianase de sìndromes de emaciação